GLP1R and metabolic dysfunction-associated steatotic liver disease: Semaglutide, which is a GLP1-RA available in subcutaneous and oral forms, is supposed to exert beneficial effects on NAFLD by numerous mechanisms of action rendering it a promising treatment for the disease (Cigrovski Berkovic et al., 2022).